Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - December 20, 2002
The submissions for registration include data from more than 1,100 treatment-naive and treatment-experienced patients who have participated in Phase III trials to evaluate the safety and efficacy of 908 in comparison with two widely used HIV protease inhibitors. In clinical trials, 908 was dosed as two tablets in both once-daily and twice-daily regimens.
"The regulatory submissions announced today represent a significant accomplishment for GSK and Vertex in 2002," said Joshua Boger, Ph.D., Chairman and CEO of Vertex. "Based on the data we have gathered in pivotal studies, we believe that 908 has the potential to be an important new option for the treatment of HIV, and one that is well-suited to the needs of today's HIV patients."
Once approved, GSK will market 908 and Vertex will co-promote in the U.S. and key markets in Europe. In connection with the regulatory filings announced today, Vertex earned a milestone payment from GlaxoSmithKline that will be realized in the fourth quarter of 2002.
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and an industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company. Vertex seeks to discover, develop, and commercialize major pharmaceutical products independently and with partners. Chemogenomics, Vertex's proprietary, systematic, genomics-based platform, is designed to accelerate the discovery of new drugs and to expand intellectual property coverage of drug candidate compounds and classes of related compounds. This approach, which targets gene families, has formed the basis for several commercial collaborations under which Vertex retains rights to downstream revenue. Vertex's first approved product is Agenerase(R) (amprenavir), a protease inhibitor, which Vertex co-promotes with GlaxoSmithKline. Vertex has more than 12 drug candidates in clinical and preclinical development to treat viral diseases, inflammation, cancer, autoimmune diseases, neurological disorders and genetic disorders.
This press release may contain forward-looking statements, including statements that 908 has the potential to be an important new option for HIV patients, and that 908 may be approved and launched in the United States and the European Union. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties, including the risk that 908 may not receive marketing approval in the United States and Europe, and that it may not prove to be successful as an important therapy for HIV patients, that could cause Vertex's actual results to vary materially. These risks and uncertainties include, in addition, those listed under Risk Factors in Vertex's Form 10-K filed with the Securities and Exchange Commission on April 1, 2002.
Agenerase(R) is a trademark of the GlaxoSmithKline group of companies.
Contacts:
Michael Partridge, Director, Corporate Communications, (617) 444-6108
Jaren Irene Madden, Media Relations Specialist, (617) 444-6750
SOURCE Vertex Pharmaceuticals Incorporated
Web Site: http://www.vpharm.com
021220
PR021237
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .